Medicare Launches Program to Cut Some GLP-1 Costs

Medicare Introduces New Program to Reduce Some GLP-1 Drug Costs

Medicare has launched a new program aimed at lowering out-of-pocket expenses for certain glucagon-like peptide-1 (GLP-1) receptor agonists. The initiative specifically targets a subset of these widely used medications, reducing costs for qualifying beneficiaries. While the program does not cover all GLP-1 drugs, it represents a significant step in addressing the financial burden these therapies impose on older adults and disabled individuals enrolled in Medicare.

GLP-1 receptor agonists, including semaglutide (marketed as Ozempic, Wegovy, and Rybelsus), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound), have become some of the most prescribed drugs globally. Originally developed for type 2 diabetes management, they have gained additional approval for weight loss and cardiovascular risk reduction. However, their high list prices, often exceeding $900 to $1,300 per month without insurance, have created significant cost challenges for patients and the healthcare system.

The new Medicare program focuses on specific GLP-1 costs that the agency selected for reduction. Not every GLP-1 medication or expense falls under this change. The effort applies to a portion of GLP-1 expenditures, targeting drugs and indications that meet certain criteria. Medicare designed the program explicitly for cost lowering, and participants who meet eligibility requirements can benefit from reduced expenses in this area.

Focus on GLP-1 Costs: What Is Included

The program centers on some GLP-1 costs that Medicare determined eligible for adjustment. This approach affects a portion of total GLP-1 spending rather than all related expenses. Medicare aimed the program at these items based on factors such as drug therapeutic category, disease indication, and patient population.

Specifically, the initiative aligns with broader Medicare drug price negotiation provisions established under the Inflation Reduction Act of 2022. This law granted the Centers for Medicare and Medicaid Services (CMS) the authority to negotiate prices directly with manufacturers for certain high-cost drugs. In August 2023, CMS announced the first 10 drugs selected for negotiation, which included several medications used for diabetes and cardiovascular conditions. Among them, some GLP-1 receptor agonists qualified for the process because they meet the criteria of being single-source drugs with high Medicare spending.

GLP-1 costs that fall under the program include those for medications approved for type 2 diabetes, where Medicare Part D coverage is standard. However, drugs approved solely for weight loss, such as Wegovy and Saxenda, currently do not have Medicare Part D coverage for that indication due to federal law excluding weight loss medications from coverage. This distinction explains why the program addresses some GLP-1 costs but not others.

The Congressional Budget Office estimated that the negotiation program could save Medicare $98.5 billion over a decade. For beneficiaries, lower negotiated prices translate directly into reduced copayments and coinsurance. Patients who use the selected GLP-1 drugs for diabetes may see their monthly costs drop significantly, potentially from hundreds of dollars to tens of dollars.

Program Role in Cost Management: Methodology and Implementation

Medicare designed the program specifically for cost lowering, applying to some GLP-1 drugs and not others. The new measure adjusts pricing for those selected items through a structured negotiation process.

The methodology involves several steps. First, CMS identifies drugs that meet statutory criteria: they account for the highest total Medicare Part D and Part B spending, have been on the market for at least seven years (for small molecule drugs) or eleven years (for biologics), and face no generic competition. For GLP-1 receptor agonists, semaglutide and liraglutide are biologics, while some formulations may be small molecules. CMS then invites manufacturers to negotiations, during which both sides exchange offers, data on therapeutic alternatives, and evidence on cost-effectiveness. If a manufacturer refuses to participate or fails to reach an agreement, they face an excise tax or may have their drug withdrawn from Medicare coverage.

Users of Medicare see this as a direct update to their prescription drug benefits. The program handles some GLP-1 costs by reducing the maximum fair price that Medicare will pay. Reductions take effect through this policy, with negotiated prices slated to become available in 2026 for the first round of drugs. For GLP-1s selected in later rounds, the timeline extends to 2027 or 2028.

A study published in JAMA Health Forum in 2023 projected that Medicare negotiation could lower prices for semaglutide by 40 to 60 percent compared to current list prices. Researchers at the University of Southern California modeled the impact using claims data and found that even modest discounts would yield substantial savings for both Medicare and beneficiaries. However, they cautioned that the actual effect depends on manufacturer compliance, drug exclusivity periods, and potential legal challenges.

Key Aspects of the Initiative: Scope and Limitations

The program remains a Medicare creation implemented under the Inflation Reduction Act. Lowering some GLP-1 costs stands as its goal. This setup provides savings on selected items, but the scope is limited by law and market dynamics.

Medicare implements the change now, with some GLP-1 costs receiving the adjustment. The effort centers on these targeted expenses, which include drugs like semaglutide (for diabetes) and potentially tirzepatide (for diabetes) when they become eligible. Drugs used for weight loss alone, such as Wegovy, remain outside the program for now because Medicare does not cover them for that purpose. This limitation means that many patients who could benefit from GLP-1s for obesity still face high costs or must pay out of pocket.

Healthcare policy experts have noted the inconsistency. Dr. Katelyn Jetelina, an epidemiologist and public health analyst, wrote in her newsletter that "the current coverage gap creates a perverse incentive: Medicare will pay for a GLP-1 drug to treat diabetes but not to treat obesity, even though the same drug works for both conditions and obesity is a root cause of many other diseases." This gap underscores why the program addresses only "some" GLP-1 costs.

Another key aspect involves manufacturer reactions. Some companies have announced plans to sue the government over the negotiation program, arguing it violates patent rights and the Fifth Amendment. Novo Nordisk and Eli Lilly, both major GLP-1 manufacturers, have indicated they may pursue legal recourse. If successful, these lawsuits could delay or alter the cost reduction timeline.

Despite these challenges, the program represents a shift in how Medicare manages drug costs. For researchers and biohackers following peptide sciences, GLP-1 receptor agonists are a prime example of peptide-based therapeutics making the transition from niche endocrinology to mainstream metabolic health. Understanding the economic and regulatory landscape around these drugs is crucial for anticipating market access, affordability, and future innovation.

Frequently Asked Questions

Q: Which GLP-1 drugs are included in the Medicare cost reduction program?

A: The program initially targets single-source GLP-1 receptor agonists that account for high Medicare spending and meet statutory criteria for price negotiation. As of now, semaglutide (Ozempic) for diabetes and liraglutide (Victoza) are likely candidates. Drugs approved only for weight loss, such as Wegovy and Saxenda, are not included because federal law prohibits Medicare from covering weight loss medications. The specific list of selected drugs will be updated periodically by CMS.

Q: When will the lower prices take effect?

A: For the first round of drugs selected in 2023, the negotiated maximum fair prices will become available starting in 2026. Additional drugs selected in subsequent rounds will see reduced prices in 2027 and 2028. Beneficiaries should check their Medicare Part D plan once these dates approach, as the exact copayment amounts depend on the plan's formulary structure.

Q: How much can patients expect to save on their GLP-1 medications?

A: The exact savings depend on the negotiated price, the beneficiary's Part D plan, and whether the drug is used for a covered indication. Modeling studies suggest discounts of 40 to 60 percent off current list prices are plausible. For a drug like Ozempic with a list price of approximately $935 per month, that could mean a maximum fair price between $374 and $561, with patient copays further reduced based on plan design.

Q: Can the program be expanded to include GLP-1 drugs for weight loss?

A: Expanding the program to cover GLP-1s for weight loss would require a change in federal law. Current Medicare statute explicitly excludes coverage of drugs prescribed for weight loss. Some lawmakers have proposed legislation to remove this restriction, but no such bill has passed. If the law changes, future rounds of negotiation could include these drugs. Until then, the program remains focused on GLP-1 costs associated with diabetes and other covered conditions.